Please login to the form below

Not currently logged in
Email:
Password:

lung cancer

This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

BMS has had mixed success in gaining NICE approval for Opdivo across its many cancer indications. ... A year ago Opdivo gained NICE approval for second line use in the biggest single cancer patient group, non-small cell lung cancer (NSCLC), but its main

Latest news

  • AZ nabs US approval for new leukaemia drug Lumoxiti AZ nabs US approval for new leukaemia drug Lumoxiti

    It has assumed greater importance for the targeted pipeline – which sits alongside AZ’s immuno-oncology R&D – since MEK Inhibitor selumetinib failed late-stage trials in thyroid cancer and lung ... National Cancer Institute (NCI) in the US, the

  • MSD wins key EU approval for Keytruda, Alimta combo MSD wins key EU approval for Keytruda, Alimta combo

    In the UK, lung cancer is the third most common cancer, with around 44, 500 diagnoses made annually. ... can renew our efforts to reach the best possible outcomes for everyone affected by lung cancer.".

  • FDA gives Loxo breakthrough tag for second cancer drug FDA gives Loxo breakthrough tag for second cancer drug

    The BTD covers patients with metastatic RET-fusion-positive non-small cell lung cancer (NSCLC) who have progressed despite earlier therapy with chemotherapy and checkpoint inhibitors, as well as last-line ... including patients with brain metastases, and

  • Home-grown colorectal cancer drug approved in China Home-grown colorectal cancer drug approved in China

    Pfizer abandoned a trial of its lung cancer drug Sutent (sunitinib) in first-line CRC a few years ago, while AstraZeneca’s cedirinib failed in this form of cancer as well ... The Chinese company is now planning to extend fruquintinib’s use into

  • Novartis wins key adjuvant Taf/Mek approval in Europe Novartis wins key adjuvant Taf/Mek approval in Europe

    including a go-ahead last year in BRAF V600-postitive non-small cell lung cancer (NSCLC). ... talk of using the cancer immunotherapies and small-molecule BRAF/MEK pair in combination.

More from news
Approximately 100 fully matching, plus 710 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have.

  • 30 Women Leaders in UK Healthcare

    use in lung cancer patients. ... She played a key role in the development and approval of Tagrisso, AstraZeneca’s next-generation EGFR-targeting lung cancer treatment that is proving a major advance on existing reatments, and

  • Cancer in The Information Age: are we illuminated or inundated? Cancer in The Information Age: are we illuminated or inundated?

    We are now on the crest of a new wave in cancer care. ... But to do this, communication is crucial. A shining example is MoovCare, a web-based application through which patients report their own symptoms of lung cancer to enable earlier detection of

  • Let’s change the conversation about cancer Let’s change the conversation about cancer

    Cancer identity is changing. Cancer has typically been defined and diagnosed by the place it originates in the body, eg lung cancer. ... As Lorraine Dallas, Director of Information and Support at the Roy Castle Lung Cancer Foundation, pointed out,

  • The good, the bad and the ugly The good, the bad and the ugly

    One commentator has remarked that while some companies’pipelines are in terrible shape, in certain therapy areas - notably cancer - innovation is so rich it could become a problem. ... Merck’s success in oncology will likely continue, driven by

More from intelligence
Approximately 1 fully matching, plus 37 partially matching documents found.

Latest appointments

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer. “

  • Merck appoints new senior vice president Merck appoints new senior vice president

    Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the ... indications including lung, cervical and breast cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics